PPARG and type 2 diabetes mellitus: Previously, we reported that PPARγ is present in rat hippocampal neurons and that its activation by thiazolidinediones (TZDs), including rosiglitazone (RGZ), ciglitazone (CGZ), and troglitazone (TGZ), PPARγ activators that have been routinely used for treatment of diabetes type 2 [15], prevented axon degeneration, neurite loss, and mitochondrial impairment induced by Aβ [11], [12].